A detailed history of Cardinal Capital Management transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Cardinal Capital Management holds 10,504 shares of CRL stock, worth $2.03 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares
10,504
Previous 10,192 3.06%
Holding current value
$2.03 Million
Previous $2.11 Million 1.71%
% of portfolio
0.33%
Previous 0.36%

Shares

33 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$187.96 - $245.29 $58,643 - $76,530
312 Added 3.06%
10,504 $2.07 Million
Q2 2024

Jul 12, 2024

BUY
$206.39 - $268.73 $76,364 - $99,430
370 Added 3.77%
10,192 $2.11 Million
Q1 2024

Jul 12, 2024

BUY
$203.52 - $273.43 $279,229 - $375,145
1,372 Added 16.24%
9,822 $2.66 Million
Q1 2024

Apr 15, 2024

BUY
$203.52 - $273.43 $279,229 - $375,145
1,372 Added 16.24%
9,822 $2.66 Million
Q4 2023

Jul 12, 2024

BUY
$164.52 - $238.84 $7,732 - $11,225
47 Added 0.56%
8,450 $2 Million
Q4 2023

Jan 26, 2024

BUY
$164.52 - $238.84 $7,732 - $11,225
47 Added 0.56%
8,450 $2 Million
Q3 2023

Jul 12, 2024

BUY
$194.44 - $217.61 $34,610 - $38,734
178 Added 2.16%
8,403 $1.65 Million
Q3 2023

Oct 16, 2023

BUY
$194.44 - $217.61 $34,610 - $38,734
178 Added 2.16%
8,403 $1.65 Million
Q2 2023

Jul 12, 2024

SELL
$183.71 - $210.25 $293,384 - $335,769
-1,597 Reduced 16.26%
8,225 $1.73 Million
Q2 2023

Jul 12, 2023

BUY
$183.71 - $210.25 $15,247 - $17,450
83 Added 1.02%
8,225 $1.73 Million
Q1 2023

Apr 18, 2023

BUY
$191.89 - $259.92 $14,007 - $18,974
73 Added 0.9%
8,142 $1.64 Million
Q4 2022

Jan 20, 2023

BUY
$197.11 - $250.07 $30,749 - $39,010
156 Added 1.97%
8,069 $0
Q3 2022

Oct 21, 2022

BUY
$182.44 - $250.54 $35,758 - $49,105
196 Added 2.54%
7,913 $1.56 Million
Q2 2022

Aug 04, 2022

BUY
$204.13 - $302.4 $10,818 - $16,027
53 Added 0.69%
7,717 $1.65 Million
Q1 2022

Apr 21, 2022

BUY
$255.51 - $362.11 $40,626 - $57,575
159 Added 2.12%
7,664 $2.18 Million
Q4 2021

Jan 18, 2022

SELL
$351.38 - $448.68 $19,677 - $25,126
-56 Reduced 0.74%
7,505 $2.83 Million
Q3 2021

Oct 21, 2021

BUY
$372.64 - $458.3 $2,981 - $3,666
8 Added 0.11%
7,561 $3.12 Million
Q2 2021

Jul 14, 2021

SELL
$294.17 - $371.65 $22,945 - $28,988
-78 Reduced 1.02%
7,553 $2.79 Million
Q1 2021

Apr 19, 2021

BUY
$249.67 - $299.48 $8,988 - $10,781
36 Added 0.47%
7,631 $2.21 Million
Q4 2020

Feb 01, 2021

BUY
$222.0 - $252.62 $14,208 - $16,167
64 Added 0.85%
7,595 $1.9 Million
Q3 2020

Oct 16, 2020

BUY
$175.56 - $226.45 $27,036 - $34,873
154 Added 2.09%
7,531 $1.71 Million
Q2 2020

Jul 16, 2020

BUY
$118.84 - $189.72 $31,730 - $50,655
267 Added 3.76%
7,377 $1.29 Million
Q1 2020

Apr 20, 2020

SELL
$98.9 - $178.34 $87,130 - $157,117
-881 Reduced 11.02%
7,110 $897,000
Q4 2019

Jan 21, 2020

SELL
$126.05 - $152.76 $16,260 - $19,706
-129 Reduced 1.59%
7,991 $1.22 Million
Q3 2019

Oct 18, 2019

SELL
$125.07 - $143.67 $14,383 - $16,522
-115 Reduced 1.4%
8,120 $1.07 Million
Q2 2019

Jul 08, 2019

SELL
$123.4 - $148.55 $25,050 - $30,155
-203 Reduced 2.41%
8,235 $1.17 Million
Q1 2019

Apr 11, 2019

SELL
$104.82 - $146.73 $2,201 - $3,081
-21 Reduced 0.25%
8,438 $1.23 Million
Q4 2018

Jan 15, 2019

BUY
$105.09 - $137.23 $14,397 - $18,800
137 Added 1.65%
8,459 $957,000
Q3 2018

Oct 25, 2018

BUY
$112.11 - $134.54 $3,026 - $3,632
27 Added 0.33%
8,322 $1.12 Million
Q2 2018

Jul 25, 2018

BUY
$102.37 - $117.25 $4,299 - $4,924
42 Added 0.51%
8,295 $931,000
Q1 2018

Apr 25, 2018

SELL
$98.19 - $115.2 $8,051 - $9,446
-82 Reduced 0.98%
8,253 $880,000
Q4 2017

Feb 01, 2018

SELL
$100.43 - $118.09 $11,248 - $13,226
-112 Reduced 1.33%
8,335 $912,000
Q3 2017

Oct 24, 2017

BUY
$96.72 - $109.26 $816,993 - $922,919
8,447
8,447 $912,000

Others Institutions Holding CRL

About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.


  • Ticker CRL
  • Exchange NYSE
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 50,863,300
  • Market Cap $9.84B
  • Description
  • Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...
More about CRL
Track This Portfolio

Track Cardinal Capital Management Portfolio

Follow Cardinal Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cardinal Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Cardinal Capital Management with notifications on news.